排序方式: 共有3条查询结果,搜索用时 656 毫秒
1
1.
In deciding whether to support an international role of their country’s currency, national policymakers are often influenced
by lobbying from domestic sectoral groups. While these groups will be consistently more interested in some implications of
international currency issuance than others, their specific preferences are likely to be highly context specific. Looking
at the cases of the United States and China, we anticipate that domestic sectoral lobbying is unlikely to pressure either
the US government to defend the dollar’s international role vigorously or the Chinese government to internationalize the renminbi
fully. From this domestic sectoral perspective, the future looks to be characterized by reluctant monetary leaders rather
than increasingly aggressive currency competition between the United States and China. 相似文献
2.
B. B. Hansen S. Nuhoho S. N. Ali T. Dang-Tan W. J. Valentine S. J. P. Malkin 《Journal of medical economics》2020,23(6):650-658
AbstractAims: The efficacy and safety of oral semaglutide, the first glucagon-like peptide-1 (GLP-1) receptor agonist developed for oral administration for the treatment of type 2 diabetes, was evaluated in the PIONEER clinical trial program, and a recently published network meta-analysis allowed comparison with further injectable GLP-1 receptor agonists. The present study aimed to assess the short-term cost- effectiveness of oral semaglutide 14?mg versus subcutaneous once-weekly dulaglutide 1.5?mg, once-weekly exenatide 2?mg, twice-daily exenatide 10?µg, once-daily liraglutide 1.8?mg, once-daily lixisenatide 20?µg, and once-weekly semaglutide 1?mg, in terms of the cost per patient achieving glycated hemoglobin (HbA1c) targets (cost of control).Materials and methods: Cost of control was calculated by dividing the annual treatment costs associated with an intervention by the proportion of patients achieving the treatment target with an intervention, with outcomes calculated for targets of HbA1c ≤6.5% and HbA1c <7.0% for all included GLP-1 receptor agonists. Annual treatment costs were accounted in 2019 United States dollars (USD), based on 2019 wholesale acquisition cost.Results: For the treatment target of HbA1c ≤6.5%, once-weekly semaglutide 1?mg and oral semaglutide 14?mg were associated with the lowest costs of control, at USD 15,430 and USD 17,383 per patient achieving target, respectively. Similarly, the cost of control was lowest with once-weekly semaglutide 1?mg at USD 12,627 per patient achieving target, followed by oral semaglutide 14?mg at USD 13,493 per patient achieving target for the target of HbA1c <7.0%. All other interventions were associated with higher cost of control values for both targets.Conclusions: Oral semaglutide 14?mg is likely to be cost-effective versus dulaglutide, exenatide (once weekly and twice daily), liraglutide, and lixisenatide in terms of bringing people with type 2 diabetes to glycemic control targets of HbA1c ≤6.5% and HbA1c <7.0% in the US. 相似文献
3.
1